Utah Medical Products (NASDAQ:UTMD) Shares Cross Above Fifty Day Moving Average – Time to Sell?

Shares of Utah Medical Products, Inc. (NASDAQ:UTMD) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $56.49 and traded as high as $58.76. Utah Medical Products shares last traded at $57.60, with a volume of 19,913 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Utah Medical Products in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Utah Medical Products has a consensus rating of “Sell”.

Utah Medical Products Price Performance

The firm has a market cap of $184.55 million, a price-to-earnings ratio of 16.27 and a beta of 0.33. The firm has a fifty day simple moving average of $56.49 and a two-hundred day simple moving average of $58.38.

Utah Medical Products (NASDAQ:UTMD) last posted its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $0.82 earnings per share (EPS) for the quarter. The firm had revenue of $9.81 million for the quarter. Utah Medical Products had a net margin of 30.08% and a return on equity of 9.89%.

Utah Medical Products Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, January 5th. Stockholders of record on Tuesday, December 16th were paid a dividend of $0.31 per share. The ex-dividend date was Tuesday, December 16th. This is an increase from Utah Medical Products’s previous quarterly dividend of $0.31. This represents a $1.24 annualized dividend and a dividend yield of 2.2%. Utah Medical Products’s payout ratio is presently 35.03%.

Hedge Funds Weigh In On Utah Medical Products

Several hedge funds have recently made changes to their positions in the company. Comerica Bank grew its stake in Utah Medical Products by 435.6% during the 3rd quarter. Comerica Bank now owns 541 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 440 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Utah Medical Products by 159.7% during the second quarter. First Horizon Advisors Inc. now owns 587 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 361 shares during the period. CWM LLC lifted its holdings in shares of Utah Medical Products by 287.4% during the second quarter. CWM LLC now owns 829 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 615 shares during the period. BNP Paribas Financial Markets boosted its position in Utah Medical Products by 89.6% in the third quarter. BNP Paribas Financial Markets now owns 1,060 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 501 shares during the last quarter. Finally, Cornerstone Planning Group LLC increased its holdings in Utah Medical Products by 3,272.5% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,349 shares of the medical instruments supplier’s stock worth $85,000 after buying an additional 1,309 shares during the period. 69.60% of the stock is owned by institutional investors and hedge funds.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single‐use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non‐invasive monitoring products used in acute and long‐term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end‐tidal carbon dioxide (CO₂).